Regenxbio (RGNX) announced the completion of enrollment in the Atmosphere and Ascent pivotal studies evaluating surabgene lomparvovec in wet age-related macular degeneration using subretinal delivery. Topline data is expected in the fourth quarter of 2026.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RGNX:
- Promising Data and Regulatory Progress Bolster Buy Rating for RegenXBio’s RGX-121
- Promising Data and Strategic Moves Position RegenXBio for Potential Success with RGX-121
- Regenxbio reports ‘positive’ results from Phase I/II/III CAMPSIITE trial
- Regenxbio FDA delay ‘not a needle mover,’ says Leerink
- Strategic Developments and Partnerships Bolster RegenXBio’s Buy Rating Amid Regulatory Delay